Literature DB >> 34021184

The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.

Lunxu Li1, Shilin Xia2, Xueying Shi2, Xu Chen1, Dong Shang3,4.   

Abstract

Hepatocellular carcinoma (HCC) is one of the main causes of cancer deaths globally. Immunotherapy is becoming increasingly important in the cure of advanced HCC. Thus it is essential to identify biomarkers for treatment response and prognosis prediction. We searched publicly available databases and retrieved 465 samples of genes from The Cancer Genome Atlas (TCGA) database and 115 tumor samples from Gene Expression Omnibus (GEO). Meanwhile, we used the ImmPort database to determine the immune-related genes as well. Weighted gene correlation network analysis, Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis were used to identify the key immune related genes (IRGs) which are closely related to prognosis. Gene set enrichment analysis (GSEA) was implemented to explore the difference of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway between Immune high- and low-risk score groups. Finally, we made a prognostic nomogram including Immune-Risk score and other clinicopathologic factors. A total of 318 genes from prognosis related modules were identified through weighted gene co-expression network analysis (WGCNA). 46 genes were strongly linked to prognosis after univariate Cox analysis. We constructed a seven genes prognostic signature which showed powerful prediction ability in both training cohort and testing cohort. 16 significant KEGG pathways were identified between high- and low- risk score groups using GSEA analysis. This study identified and verified seven immune-related prognostic biomarkers for the patients with HCC, which have potential value for immune modulatory and therapeutic targets.

Entities:  

Year:  2021        PMID: 34021184     DOI: 10.1038/s41598-021-89747-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  63 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

3.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 4.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

Review 5.  Goals and targets for personalized therapy for HCC.

Authors:  Thomas Couri; Anjana Pillai
Journal:  Hepatol Int       Date:  2019-01-01       Impact factor: 6.047

6.  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

Authors:  John D Gordan; Erin B Kennedy; Ghassan K Abou-Alfa; Muhammad Shaalan Beg; Steven T Brower; Terence P Gade; Laura Goff; Shilpi Gupta; Jennifer Guy; William P Harris; Renuka Iyer; Ishmael Jaiyesimi; Minaxi Jhawer; Asha Karippot; Ahmed O Kaseb; R Kate Kelley; Jennifer J Knox; Jeremy Kortmansky; Andrea Leaf; William M Remak; Rachna T Shroff; Davendra P S Sohal; Tamar H Taddei; Neeta K Venepalli; Andrea Wilson; Andrew X Zhu; Michal G Rose
Journal:  J Clin Oncol       Date:  2020-11-16       Impact factor: 44.544

7.  Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer.

Authors:  Kumardeep Chaudhary; Olivier B Poirion; Liangqun Lu; Lana X Garmire
Journal:  Clin Cancer Res       Date:  2017-10-05       Impact factor: 12.531

Review 8.  Recent developments with immunotherapy for hepatocellular carcinoma.

Authors:  Oliver Waidmann
Journal:  Expert Opin Biol Ther       Date:  2018-07-20       Impact factor: 4.388

Review 9.  Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

Authors:  Yingjun Xie; Yien Xiang; Jiyao Sheng; Dan Zhang; Xiaoxiao Yao; Yongsheng Yang; Xuewen Zhang
Journal:  J Immunol Res       Date:  2018-03-26       Impact factor: 4.818

10.  GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.

Authors:  R Lencioni; M Kudo; S-L Ye; J-P Bronowicki; X-P Chen; L Dagher; J Furuse; J F Geschwind; L Ladrón de Guevara; C Papandreou; T Takayama; S K Yoon; K Nakajima; R Lehr; S Heldner; A J Sanyal
Journal:  Int J Clin Pract       Date:  2013-11-28       Impact factor: 2.503

View more
  1 in total

1.  Immunoautophagy-Related Long Noncoding RNA (IAR-lncRNA) Signature Predicts Survival in Hepatocellular Carcinoma.

Authors:  Yulu Wang; Fangfang Ge; Amit Sharma; Oliver Rudan; Maria F Setiawan; Maria A Gonzalez-Carmona; Miroslaw T Kornek; Christian P Strassburg; Matthias Schmid; Ingo G H Schmidt-Wolf
Journal:  Biology (Basel)       Date:  2021-12-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.